# N.CER Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/n-cer-co

- Industry: Medical Devices & Equipment
- Headquarters: Gwangju, South Korea
- Website: www.ncerebro.com
- Total disclosed funding: $1.9M
- Latest round: Series A (Aug 20, 2021)
- Investors on record: 6

## About

Based in Gwangju, South Korea, and founded in 2019, N.CER is a solution developer for early diagnosis of dementia with technology transfer from Gwangju Institute of Science and Technology or GIST. In 2020, the company completed its prototype, given approval by the Ministry of Food and Drug Safety, and signed an MOU with Daewoong Pharmaceutical DIC. In the same year, N.CER signed a contract for the Gwangju Dementia Cohort Research Center Research and the Gangnam Severance Hospital Psychiatry Consignment Research, followed by the establishment of an affiliated research institute.

The company provides services for early diagnosis and prevention of dementia based on changes in brain blood flow during sensory stimulation.

N.CER plans to improve the accuracy of early detection of dementia and speed up the licensing of related technologies by increasing the clinical sample group from 100 to 500 and advancing the AI ??system to identify previously undiscovered patients between normal and early dementia.

## Funding rounds

- Series A, Aug 20, 2021, $1.9M — Coolidge Corner Investment, DT&Investment, Cosine Investment, Enlight Ventures, G1 IP LAW FIRM, Venture Box

## Investors

- Coolidge Corner Investment (https://capitalatlas.ai/funds/coolidge-corner-investment) — Series A
- DT&Investment (https://capitalatlas.ai/funds/dt-investment) — Series A
- Cosine Investment — Series A
- Enlight Ventures (https://capitalatlas.ai/funds/enlight-ventures) — Series A
- G1 IP LAW FIRM — Series A
- Venture Box — Series A